BGB-16673 vs. Pirtobrutinib in patients w/relapsed/refractory CLL or SLL

A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Disease Types: Leukemia, Lymphoma

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

For More Information:

https://clinicaltrials.gov/study/NCT06973187?term=BGB-16673%20in%20CLL&rank=3